Contact us
Menu
Contact us
BCC

Basal Cell Carcinoma at a Glance

Basal cell carcinoma (BCC) is the most common form of skin cancer.  

 
Basal Cell Carcinoma

Affects 3.6 million people each
year in North America

Basal Cell Carcinoma

Primarily caused by 
cumulative sun exposure 

Basal Cell Carcinoma

Most commonly develops on
sun exposed areas such as the
face, neck, and scalp 

Basal Cell Carcinoma

Although surgery is standard of care, 
there remains a need for treatments that preserve
skin, minimize discomfort, and allow patients
to return to their daily lives promptly


BCC Subtypes and Treatments

BCCs start in basal layer of the skin and can appear in different forms depending on how they grow within the skin layers. 

Superficial BCC (≈15% of cases) 
Usually treated with topical medications, such as creams, applied directly to the skin. 

Advanced or Metastatic BCC (≈1-10% of cases) 
Treated with systemic therapies such as Hedgehog pathway inhibitors, or surgery. 

Nodular BCC (≈60-80% of cases)  
It is slow-growing, non-aggressive, and rarely metastasizes. However, if neglected, it can cause local tissue and bone destruction. It is most commonly treated with surgical excision, including Mohs surgery, which is often referred to as the gold standard.

Skin Layers


Understanding Nodular BCC Care 

Mohs surgery is widely considered the gold-standard surgical technique for nodular basal cell carcinomas (nBCC), particularly when located in cosmetically sensitive or high-risk areas. The procedure involves removing thin layers of skin one at a time and examining each layer microscopically until no cancer cells remain. 
 
While Mohs surgery is highly effective and remains a standard treatment approach for nBCC, it is a surgical procedure that may require extended procedural time, local wound care, and a recovery period. Cosmetic changes to the treated skin, including scarring or discoloration, may occur. Some patients may require multiple procedures over time depending on disease recurrence or the number of lesions treated. 

This underscores continued interest in evaluating additional treatment approaches for patients with nBCC.
Mohs Surgery
FLD-103 Treatment

FLD-103: An Investigational Non-Surgical Treatment for nBCC by Feldan Therapeutics

FLD-103 is an investigational therapy currently in Phase 1 clinical development for nodular basal cell carcinoma (nBCC). Studies are evaluating the local administration of FLD-103 directly into the tumor, as well as its safety, tolerability, and potential effects on tumor and surrounding tissue.

FLD-103: An Investigational Non-Surgical Treatment for nBCC by Feldan Therapeutics

FLD-103 is an investigational therapy currently in Phase 1 clinical development for nodular basal cell carcinoma (nBCC). Studies are evaluating the local administration of FLD-103 directly into the tumor, as well as its safety, tolerability, and potential effects on tumor and surrounding tissue.

Non-Surgical Approach

FLD-103 is being studied as a non-surgical treatment approach for nBCC

Cosmetic Considerations

Clinical studies are evaluating the potential effects of FLD-103 on surrounding tissue and cosmetic outcomes related to treatments

Patient Access and Treatment Journey

FLD-103 is being studied with the intent to support improved access to treatment and to enhance the patient treatment journey

Our healthy cells use different signaling systems to guide how they grow and develop. In healthy adult skin, one of these systems—called the Hedgehog pathway (HHP)—is usually switched off. In basal cell carcinoma, this pathway is abnormally active, sending signals that drive cancer cell growth.

FLD-103 has been designed to interact with components of the HHP, which is involved in BCC biology.

FLD-103 MoA Simplified (Patients)

FLD-103 Clinical Trial Status

FLD-103 is an investigational treatment currently being evaluated in Phase 1 clinical trials and has not yet been approved for general use.

The Phase 1 clinical trial of FLD-103 is being conducted in Australia across multiple clinical sites under the oversight of Feldan's Australian subsidiary (Feldan Australia Pty Ltd).

*This page provides patients and families with general information about the medical conditions for which we are advancing new therapeutics, the unmet needs they are intended to address and the science behind our approach. The content is intended to be informative and supportive and does not replace personalized medical advice. Our therapies are investigational, which means they are still being studied and have not yet been approved by regulatory agencies such as the Food and Drug Administration (FDA) or Health Canada. Their safety and efficacy have not been established, and they may have risks and side effects that are not yet fully understood. Any data presented are preliminary and subject to change until study completion and regulatory review.